## REFERENCES


1. A.H. de Boer, H.K. Chan, R. Price, (2012), A critical view on lactose-based drug formulation and device studies for dry powder inhalation: Which are relevant and what interactions to expect?; Advanced Drug Delivery Reviews 64; 257–274.
2. Ada S. Cowan, Richard S. Brody, (2011), Protein Stabilization; Patent application number:20110014676.
3. Andreas Abend, Allen Templeton, (2010),"The Impact of Stopper Drying for Lyophilized Drug Products" from American pharmaceutical review, 25(6), 201-206.
4. Ankit Baheti, Lokesh Kumar, Arvind K. Bansal,(2010), Excipients used in lyophilization of small molecules, J. Excipients and Food Chem. 1;1
5. Dave A. Parkins, (2000), The formulation of biopharmaceuticalProducts from PSTT Vol. 3, No. 4.
6. Dave A. Parkins, Ulla T. Lashmar, (2000), The formulation of biopharmaceutical products; PSTT Vol. 3, No. 4 April.
7. David S. Pearson, and Geoff Smith (1998), Dielectric analysis as a tool for investigating the lyophilization of proteins; PSTT Vol. 1, No. 3 June.
8. De Rosier, (2011), Method and formulation for stabilization of enzymes; United States Patent 6294365.
9. Deirdre Murphy Piedmonte, Michael J. Treuheit, (2008), Formulation of Neulasta® (pegfilgrastim), Advanced Drug Delivery Reviews 60;50–58.
10. Dr. Jay Goldring, (2009) Novel Excipients: The Next Pharmaceutical Frontier? Drug Delivery, American pharmaceutical review
11. Dr. Thanaset Senawong, (2008) Lyophilization: Biochemistry, Science KKU
12. Edward T. Maggio, (2008), Novel Excipients Prevent Aggregation in Manufacturing and Formulation of Protein and Peptide Therapeutics; BioProcess International, November.
13. EMA, scientific guideline for Novel excipient, (2003), from website, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003388.pdf).

14. G. Fotsing, M. Fillet, I. Bechet, Ph. Hubert, J. Crommen, (1997), Determination of six water-soluble vitamins in a pharmaceutical formulation by capillary electrophoresis; Journal of Pharmaceutical and Biomedical Analysis 15; 1113-1123
15. G.A. Magee, G.W. Halbert, N. Wilmott, (1995), Effect of process variables on the in vitro degradationof protein microspheres; Journal of Controlled Release 37, 11-19.
16. Giorgio Pifferi, (2003), The safety of pharmaceutical excipients from II Farmaco Volume 58, Issue 8, Pages 541-550
17. Girish K Jani, (2009), Gums and mucilages/Asian Journal of Pharmaceutical Sciences 2009, 4 (5): 309-323
18. Guidance for Industry: Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), and Center for Biologics Evaluation and Research (CBER) 2005[Last accessed 6 July 2009]• Regulatory insight into the choice of excipients).
19. Guideline on Excipients in the Dossier for Application for Marketing Authorization of a Medicinal Product, EMEA/CHMP/QWP/396951/2006. European Medicines Agency. 2007. Available from: http://www.emea.europa.eu/pdfs/human/qwp/39695106enfin.pdf [Last accessed 6 July 2009]• Regulatory insight into the choice of excipients.
20. H.H. Kwak, (2009), Development of a sustained-release recombinant human growth hormone formulation from Journal of Controlled Release 137; 160–165.
21. Hong Zhao, Elizabeth M. Topp, (2008), Recent U.S. Patents on Protein Drug Formulation: 2000-2007; Recent Patents on Drug Delivery & Formulation, 2, 200-208.
22. Hsu, Chung C, Nguyen, Hoc M, Wu, Sylvia S, (1993), Reconstitutable lyophilized protein formulation; United States Patent 5192743.
23. Ingrid J. Castellanos, Ruben Crespo, Kai Griebenow, (2003), Poly(ethylene glycol) as stabilizer and emulsifying agent: a novel stabilization approach preventing aggregation and inactivation of proteins upon encapsulation in bio erodiblepolyester microspheres; Journal of Controlled Release 88, 135–145.
24. J.E. Martı n-Alfonso, C. Valencia, M.C. Sanchez, J.M. Franco, C. Gallegos, (2007), Development of new lubricating grease formulations using recycled LDPE as rheology modifier additive, European Polymer Journal 43; 139–149.

25. James Taylor, (2006), Current Trends and Challenges in the Excipients Market from Pharmaceutical Technology, Oct. 1.
26. Jennings, T. A. (1999). Lyophilization: Introduction and Basic Principles, Interpharm Press, 87-118.
27. K. Lakshmi Narasimha Rao, (2012), explains the Development and validation of a stability-indicatingLC method for simultaneous determination ofrelated compounds of guaifenesin, terbutaline sulfate and ambroxol HCl in cough syrup formulation, Journal of Saudi Chemical Society Received 16 October 2011; accepted 18 January 2012.
28. Kate Denton, (2010),Regulatory challenges are hinderingthe use of novel excipients, from Pharmaceutical Technology, July 2010.
29. Katharina Woertz, Corinna Tissen, Peter Kleinebudde, Jörg Breitkreutz, (2011) comparative study on two electronic tongues for pharmaceutical formulationdevelopment Journal of Pharmaceutical and Biomedical Analysis 55 272–281
30. Lei Yu, Lei Yu, Alona Vizel, Mary Beth Huff, Meagan Young, Richard L. Remmele Jr., Bing He, (2006),Investigation of N-terminal glutamate cyclization of recombinant monoclonal antibody in formulation development; Journal of Pharmaceutical and Biomedical Analysis 42; 455–463.
31. Mahesh V. Chaubal, (2004), Application of formulation technologies in lead candidate selection and optimization, DDT Vol. 9, No. 14.
32. Matthews B, (2002), Excipients for non-oral routes of administration. Regulatory insight into the choice of excipients,Regul Aff J;897-908
33. R. Nageswara Rao, (2008), provides insights about the, Development of a validated RP-LC/ESI-MS–MS method forseparation, identification and determination of relatedsubstances of tamsulosin in bulk drugs and formulations from Journal of Pharmaceutical and Biomedical Analysis 46; 94–103.
34. Rajan K. Verma, (2002), Formulation aspects in the development of osmotically controlled oral drug delivery systems from Journal of Controlled Release 79; 7–27.
35. Rajan K. Verma1, Sanjay Garg, (2004), Compatibility studies between isosorbide mononitrate and selected excipients used in the development of extended release formulations, Journal of Pharmaceutical and Biomedical Analysis 35;449–458.

36. Richard S. Kaye, Tarlochan S. Purewal Oya H. Alpar, (2009), Development and testing of particulate formulations for the nasaldelivery of antibodies, Journal of Controlled Release 135; 127–135
37. Sampath Krishnan, Wenjin Cao, Joseph Phillips, (2009), Applying Raman Spectroscopy toDesign of Lyophilization Cycles forProtein Formulation Development; APR September, October.
38. Sebastian Vonhoff, (2010),Implementation of an FTIR calibration curve for fast and objective determination of changes in protein secondary structure during formulation development from Journal of Pharmaceutical and Biomedical Analysis 51: 39–45.
39. Sebastian Vonhoff, Jamie Condliffeb, Heiko Schiffter, (2010), Implementation of an FTIR calibration curve for fast and objective determination of changes in protein secondary structure during formulation development; Journal of Pharmaceutical and Biomedical Analysis 51; 39–45.
40. Shengmin Sua, Yunqiu Yua, Wei Mob, Yanling Zhang, Houyan Song, Qinfen Chenc, Yi Xie, (2008), A development of LC–MS method combining ultrafiltration and lyophilizationfor determination of r-RGD-Hirudin in human serum; Journal of Chromatography B, 870, 27–31.
41. Shireesh P.Apte , (2003)Emerging Excipients in Parenteral Medications from Pharmaceutical Technology
42. Short, Robert, e., Los Gatos, (1999), a novel excipient for the lyophilization of aqueous suspensions of microparticles; WO 2000/006124.
43. Thomas J. Anchordoquy, S. Dean Allison, Marion d.C. Molina,Lorinda G. Girouard and Taylor K. Carson (2001), Physical stabilization of DNA-based therapeutic; DDT Vol. 6, No. 9 May.
44. Tim J. Kamerzell, (2011), Protein–excipient interactions: Mechanisms and biophysical characterization appliedto protein formulation development, Advanced Drug Delivery Reviews 63 (2011) 1118–1159.
45. Tim J. Kamerzell, Reza Esfandiary, Sangeeta B. Joshi, C. Russell Middaugh, David B. Volkin (2011), Protein–excipient interactions: Mechanisms and biophysical characterization appliedto protein formulation development; Advanced Drug Delivery Reviews 63, 1118–1159.

46. Tim Serno, Raimund Geidobler, Gerhard Winter, (2011), Protein stabilization by cyclodextrins in the liquid and dried state; Advanced Drug Delivery Reviews 63; 1086–1106.
47. Tsutomu Arakawaa, Steven J. Prestrelskia, William C. Kenneya,b John F. Carpenter, (2001), Factors affecting short-term and long-term stabilities of proteins; Advanced Drug Delivery Reviews 46, 307–326.
48. V. Jannin, (2008), The Approaches for the development of solid and semi-solidlipid-based formulations from Advanced Drug Delivery Reviews 60; 734–746.
49. Venkata R. Garigapati, (2008), Protein stabilization formulations; US 2008/0147077 A1.
50. Wei-Guo Dai, Crystal Pollock-Dove, Liang C. Dong, Shu Li (2008), Advanced screening assays to rapidly identify solubility-enhancing formulations; Advanced Drug Delivery Reviews 60 ; 657–672.
51. Yichun Sun, (2004),Issues and challenges in developing long-acting veterinary antibiotic formulations from Advanced Drug Delivery Reviews 56; 1481–1496.
52. Yunhui Wu, (2007),Nanosizing — Oral formulation development and biopharmaceutical evaluation, Advanced Drug Delivery Reviews 59 (2007) 631–644